Incorporating Individual-Level Treatment Effects and Outcome Preferences Into Personalized Blood Pressure Target Recommendations
There are no shared decision-making frameworks for selecting blood pressure (BP) targets for individuals with hypertension. This study addressed whether results from the SPRINT (Systolic Blood Pressure Intervention Trial) could be tailored to individuals using predicted risks and simulated preferenc...
Saved in:
Published in | Journal of the American Heart Association Vol. 13; no. 16; p. e033995 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley
20.08.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | There are no shared decision-making frameworks for selecting blood pressure (BP) targets for individuals with hypertension. This study addressed whether results from the SPRINT (Systolic Blood Pressure Intervention Trial) could be tailored to individuals using predicted risks and simulated preferences.
Among 8202 SPRINT participants, Cox models were developed and internally validated to predict each individual's absolute difference in risk from intensive versus standard BP lowering for cardiovascular events, cognitive impairment, death, and serious adverse events (AEs). Individual treatment effects were combined using simulated preference weights into a net benefit, which represents a weighted sum of risk differences across outcomes. Net benefits were compared among those above versus below the median AE risk. In simulations for which cardiovascular, cognitive, and death events had much greater weight than the AEs of BP lowering, the median net benefit was 3.3 percentage points (interquartile range [IQR], 2.0-5.7), and 100% of participants had a net benefit favoring intensive BP lowering. When simulating benefits and harms to have similar weights, the median net benefit was 0.8 percentage points (IQR, 0.2-2.2), and 87% had a positive net benefit. Compared with participants at lower risk of AEs from BP lowering, those at higher risk had a greater net benefit from intensive BP lowering despite experiencing more AEs (
<0.001 in both simulations).
Most SPRINT participants had a predicted net benefit that favored intensive BP lowering, but the degree of net benefit varied considerably. Tailoring BP targets using each patient's risks and preferences may provide more refined BP target recommendations. |
---|---|
AbstractList | There are no shared decision-making frameworks for selecting blood pressure (BP) targets for individuals with hypertension. This study addressed whether results from the SPRINT (Systolic Blood Pressure Intervention Trial) could be tailored to individuals using predicted risks and simulated preferences.BACKGROUNDThere are no shared decision-making frameworks for selecting blood pressure (BP) targets for individuals with hypertension. This study addressed whether results from the SPRINT (Systolic Blood Pressure Intervention Trial) could be tailored to individuals using predicted risks and simulated preferences.Among 8202 SPRINT participants, Cox models were developed and internally validated to predict each individual's absolute difference in risk from intensive versus standard BP lowering for cardiovascular events, cognitive impairment, death, and serious adverse events (AEs). Individual treatment effects were combined using simulated preference weights into a net benefit, which represents a weighted sum of risk differences across outcomes. Net benefits were compared among those above versus below the median AE risk. In simulations for which cardiovascular, cognitive, and death events had much greater weight than the AEs of BP lowering, the median net benefit was 3.3 percentage points (interquartile range [IQR], 2.0-5.7), and 100% of participants had a net benefit favoring intensive BP lowering. When simulating benefits and harms to have similar weights, the median net benefit was 0.8 percentage points (IQR, 0.2-2.2), and 87% had a positive net benefit. Compared with participants at lower risk of AEs from BP lowering, those at higher risk had a greater net benefit from intensive BP lowering despite experiencing more AEs (P<0.001 in both simulations).METHODS AND RESULTSAmong 8202 SPRINT participants, Cox models were developed and internally validated to predict each individual's absolute difference in risk from intensive versus standard BP lowering for cardiovascular events, cognitive impairment, death, and serious adverse events (AEs). Individual treatment effects were combined using simulated preference weights into a net benefit, which represents a weighted sum of risk differences across outcomes. Net benefits were compared among those above versus below the median AE risk. In simulations for which cardiovascular, cognitive, and death events had much greater weight than the AEs of BP lowering, the median net benefit was 3.3 percentage points (interquartile range [IQR], 2.0-5.7), and 100% of participants had a net benefit favoring intensive BP lowering. When simulating benefits and harms to have similar weights, the median net benefit was 0.8 percentage points (IQR, 0.2-2.2), and 87% had a positive net benefit. Compared with participants at lower risk of AEs from BP lowering, those at higher risk had a greater net benefit from intensive BP lowering despite experiencing more AEs (P<0.001 in both simulations).Most SPRINT participants had a predicted net benefit that favored intensive BP lowering, but the degree of net benefit varied considerably. Tailoring BP targets using each patient's risks and preferences may provide more refined BP target recommendations.CONCLUSIONSMost SPRINT participants had a predicted net benefit that favored intensive BP lowering, but the degree of net benefit varied considerably. Tailoring BP targets using each patient's risks and preferences may provide more refined BP target recommendations. Background There are no shared decision‐making frameworks for selecting blood pressure (BP) targets for individuals with hypertension. This study addressed whether results from the SPRINT (Systolic Blood Pressure Intervention Trial) could be tailored to individuals using predicted risks and simulated preferences. Methods and Results Among 8202 SPRINT participants, Cox models were developed and internally validated to predict each individual's absolute difference in risk from intensive versus standard BP lowering for cardiovascular events, cognitive impairment, death, and serious adverse events (AEs). Individual treatment effects were combined using simulated preference weights into a net benefit, which represents a weighted sum of risk differences across outcomes. Net benefits were compared among those above versus below the median AE risk. In simulations for which cardiovascular, cognitive, and death events had much greater weight than the AEs of BP lowering, the median net benefit was 3.3 percentage points (interquartile range [IQR], 2.0–5.7), and 100% of participants had a net benefit favoring intensive BP lowering. When simulating benefits and harms to have similar weights, the median net benefit was 0.8 percentage points (IQR, 0.2–2.2), and 87% had a positive net benefit. Compared with participants at lower risk of AEs from BP lowering, those at higher risk had a greater net benefit from intensive BP lowering despite experiencing more AEs (P<0.001 in both simulations). Conclusions Most SPRINT participants had a predicted net benefit that favored intensive BP lowering, but the degree of net benefit varied considerably. Tailoring BP targets using each patient's risks and preferences may provide more refined BP target recommendations. There are no shared decision-making frameworks for selecting blood pressure (BP) targets for individuals with hypertension. This study addressed whether results from the SPRINT (Systolic Blood Pressure Intervention Trial) could be tailored to individuals using predicted risks and simulated preferences. Among 8202 SPRINT participants, Cox models were developed and internally validated to predict each individual's absolute difference in risk from intensive versus standard BP lowering for cardiovascular events, cognitive impairment, death, and serious adverse events (AEs). Individual treatment effects were combined using simulated preference weights into a net benefit, which represents a weighted sum of risk differences across outcomes. Net benefits were compared among those above versus below the median AE risk. In simulations for which cardiovascular, cognitive, and death events had much greater weight than the AEs of BP lowering, the median net benefit was 3.3 percentage points (interquartile range [IQR], 2.0-5.7), and 100% of participants had a net benefit favoring intensive BP lowering. When simulating benefits and harms to have similar weights, the median net benefit was 0.8 percentage points (IQR, 0.2-2.2), and 87% had a positive net benefit. Compared with participants at lower risk of AEs from BP lowering, those at higher risk had a greater net benefit from intensive BP lowering despite experiencing more AEs ( <0.001 in both simulations). Most SPRINT participants had a predicted net benefit that favored intensive BP lowering, but the degree of net benefit varied considerably. Tailoring BP targets using each patient's risks and preferences may provide more refined BP target recommendations. |
Author | Scherzer, Rebecca Killeen, Anthony A Berry, Jarett D Kravitz, Richard L Estrella, Michelle M Tancredi, Daniel J Ix, Joachim H Ascher, Simon B Shlipak, Michael G de Lemos, James A |
Author_xml | – sequence: 1 givenname: Simon B orcidid: 0000-0003-3465-4208 surname: Ascher fullname: Ascher, Simon B organization: Department of Internal Medicine University of California Davis Sacramento CA – sequence: 2 givenname: Richard L orcidid: 0000-0001-5575-529X surname: Kravitz fullname: Kravitz, Richard L organization: Department of Internal Medicine University of California Davis Sacramento CA – sequence: 3 givenname: Rebecca orcidid: 0000-0002-1579-5390 surname: Scherzer fullname: Scherzer, Rebecca organization: Department of Internal Medicine, Kidney Health Research Collaborative San Francisco Veterans Affairs Health Care System and University of California San Francisco San Francisco CA – sequence: 4 givenname: Jarett D orcidid: 0000-0002-5004-8155 surname: Berry fullname: Berry, Jarett D organization: Department of Internal Medicine University of Texas at Tyler Health Science Center Tyler TX – sequence: 5 givenname: James A orcidid: 0000-0003-2211-7261 surname: de Lemos fullname: de Lemos, James A organization: Division of Cardiology, Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX – sequence: 6 givenname: Michelle M orcidid: 0000-0002-8902-9576 surname: Estrella fullname: Estrella, Michelle M organization: Department of Internal Medicine, Kidney Health Research Collaborative San Francisco Veterans Affairs Health Care System and University of California San Francisco San Francisco CA – sequence: 7 givenname: Daniel J orcidid: 0000-0002-3884-7907 surname: Tancredi fullname: Tancredi, Daniel J organization: Department of Pediatrics University of California Davis Sacramento CA – sequence: 8 givenname: Anthony A orcidid: 0000-0003-1629-9468 surname: Killeen fullname: Killeen, Anthony A organization: Department of Laboratory Medicine and Pathology University of Minnesota Minneapolis MN – sequence: 9 givenname: Joachim H orcidid: 0000-0002-8084-9869 surname: Ix fullname: Ix, Joachim H organization: Nephrology Section, Veterans Affairs San Diego Healthcare System San Diego CA – sequence: 10 givenname: Michael G orcidid: 0000-0002-9559-204X surname: Shlipak fullname: Shlipak, Michael G organization: Department of Internal Medicine, Kidney Health Research Collaborative San Francisco Veterans Affairs Health Care System and University of California San Francisco San Francisco CA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39136305$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkU1v1DAURS1UREvpmh3ykk2mThx_ZDlUhQ4aqRUa1taL_TJKldiD7VSCFT8dD1MqvLH1dO95ks9bcuaDR0Le12xV17K-_rq-W6_qpl0xzrtOvCIXDWtV1XWanf33PidXKT2ycmSjuOjekHPe1VxyJi7I7423IR5ChDz6Pd14Nz6NboGp2uITTnQXEfKMPtPbYUCbEwXv6P2SbZiRPkQcMKK3mEo1B_qAMQUP0_gLHf00heCOmZSWiHQHcY-ZfsNSLURXNgaf3pHXA0wJr57vS_L98-3u5q7a3n_Z3Ky3lW20zpUWUgxWgmStHrh0TKFG2SvbDK3oUPESAIWMgXW65rwFJlzTt7bMpbCaX5LNiesCPJpDHGeIP02A0fwdhLg3EPNoJzQ91r1AJUHoAh-g5wXUtpqBVMzyvrA-nliHGH4smLKZx2RxmsBjWJLhrGu4lKoVJXp9itoYUirf9bK6ZuZo0RwtmmLRnCyWxodn-NLP6F7y_5zxP80Ymso |
Cites_doi | 10.1177/2515245919898657 10.1001/jama.2020.14545 10.7326/M18-3667 10.1136/bmjopen-2018-028438 10.1136/bmj.d5888 10.1161/CIRCULATIONAHA.123.064003 10.1002/sim.8570 10.1016/j.eclinm.2023.102012 10.1186/s12955-019-1250-6 10.1161/HYPERTENSIONAHA.123.21323 10.1001/jama.2016.19043 10.1016/S0140-6736(16)31679-8 10.1001/jama.2018.21442 10.1056/NEJMoa1511939 10.1214/ss/1009212519 10.1001/jama.2016.7050 10.1016/j.kint.2020.11.003 10.7326/M22-0844 10.1016/j.jacc.2021.02.058 10.1186/s12916-015-0493-2 10.1038/s41746-019-0156-3 10.1093/eurheartj/ehu004 10.1093/jnci/91.21.1829 10.1016/j.jacc.2021.03.230 10.1080/01621459.1999.10474144 10.1093/eurheartj/ehy339 10.1177/1740774514537404 10.1161/CIRCHEARTFAILURE.116.003613 10.1016/j.jacc.2018.01.074 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 10.1161/CIRCOUTCOMES.117.003624 10.1371/journal.pmed.1002410 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 DOA |
DOI | 10.1161/JAHA.124.033995 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2047-9980 |
ExternalDocumentID | oai_doaj_org_article_be1b5e76a58f45fab32b44480a670c3b 10_1161_JAHA_124_033995 39136305 |
Genre | Randomized Controlled Trial Multicenter Study Journal Article |
GroupedDBID | 0R~ 1OC 24P 53G 5VS 8-1 AAZKR ACGFO ACXQS ADBBV ADKYN ADZMN AEGXH AENEX AIAGR ALAGY ALMA_UNASSIGNED_HOLDINGS AOIJS AVUZU BAWUL BCNDV CGR CUY CVF DIK EBS ECM EIF EMOBN GODZA GROUPED_DOAJ GX1 HYE KQ8 M~E NPM OK1 RAH RHF RNS RPM WIN AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c288t-8565fc6a6048f36d07e8e6b7c2f459e73856a7e00acd81334a05d2b4c85665c83 |
IEDL.DBID | DOA |
ISSN | 2047-9980 |
IngestDate | Thu Dec 05 08:01:58 EST 2024 Sat Oct 26 04:19:07 EDT 2024 Fri Dec 06 07:06:34 EST 2024 Sat Nov 02 12:30:44 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 16 |
Keywords | prediction precision medicine hypertension shared decision‐making patient preferences |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c288t-8565fc6a6048f36d07e8e6b7c2f459e73856a7e00acd81334a05d2b4c85665c83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0002-8902-9576 0000-0002-3884-7907 0000-0002-9559-204X 0000-0002-5004-8155 0000-0003-3465-4208 0000-0003-2211-7261 0000-0002-1579-5390 0000-0003-1629-9468 0000-0001-5575-529X 0000-0002-8084-9869 |
OpenAccessLink | https://doaj.org/article/be1b5e76a58f45fab32b44480a670c3b |
PMID | 39136305 |
PQID | 3092366745 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_be1b5e76a58f45fab32b44480a670c3b proquest_miscellaneous_3092366745 crossref_primary_10_1161_JAHA_124_033995 pubmed_primary_39136305 |
PublicationCentury | 2000 |
PublicationDate | 2024-08-20 |
PublicationDateYYYYMMDD | 2024-08-20 |
PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-20 day: 20 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of the American Heart Association |
PublicationTitleAlternate | J Am Heart Assoc |
PublicationYear | 2024 |
Publisher | Wiley |
Publisher_xml | – sequence: 0 name: Wiley |
References | e_1_3_2_26_2 e_1_3_2_27_2 e_1_3_2_28_2 Whelton PK (e_1_3_2_6_2) 2017; 2018 e_1_3_2_29_2 e_1_3_2_20_2 e_1_3_2_21_2 e_1_3_2_22_2 e_1_3_2_23_2 Coles S (e_1_3_2_9_2) 2022; 106 e_1_3_2_24_2 e_1_3_2_25_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_18_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_2_2 e_1_3_2_14_2 e_1_3_2_35_2 |
References_xml | – ident: e_1_3_2_21_2 doi: 10.1177/2515245919898657 – ident: e_1_3_2_5_2 doi: 10.1001/jama.2020.14545 – ident: e_1_3_2_22_2 doi: 10.7326/M18-3667 – ident: e_1_3_2_16_2 doi: 10.1136/bmjopen-2018-028438 – ident: e_1_3_2_26_2 doi: 10.1136/bmj.d5888 – ident: e_1_3_2_34_2 doi: 10.1161/CIRCULATIONAHA.123.064003 – ident: e_1_3_2_25_2 doi: 10.1002/sim.8570 – ident: e_1_3_2_30_2 doi: 10.1016/j.eclinm.2023.102012 – ident: e_1_3_2_15_2 doi: 10.1186/s12955-019-1250-6 – ident: e_1_3_2_35_2 doi: 10.1161/HYPERTENSIONAHA.123.21323 – ident: e_1_3_2_2_2 doi: 10.1001/jama.2016.19043 – ident: e_1_3_2_3_2 doi: 10.1016/S0140-6736(16)31679-8 – ident: e_1_3_2_17_2 doi: 10.1001/jama.2018.21442 – ident: e_1_3_2_4_2 doi: 10.1056/NEJMoa1511939 – ident: e_1_3_2_20_2 doi: 10.1214/ss/1009212519 – ident: e_1_3_2_33_2 doi: 10.1001/jama.2016.7050 – ident: e_1_3_2_8_2 doi: 10.1016/j.kint.2020.11.003 – ident: e_1_3_2_24_2 doi: 10.7326/M22-0844 – ident: e_1_3_2_12_2 doi: 10.1016/j.jacc.2021.02.058 – ident: e_1_3_2_28_2 doi: 10.1186/s12916-015-0493-2 – ident: e_1_3_2_14_2 doi: 10.1038/s41746-019-0156-3 – ident: e_1_3_2_27_2 doi: 10.1093/eurheartj/ehu004 – ident: e_1_3_2_13_2 doi: 10.1093/jnci/91.21.1829 – ident: e_1_3_2_32_2 doi: 10.1016/j.jacc.2021.03.230 – ident: e_1_3_2_29_2 doi: 10.1080/01621459.1999.10474144 – volume: 106 year: 2022 ident: e_1_3_2_9_2 article-title: Blood pressure targets in adults with hypertension: a clinical practice guideline from the AAFP publication-title: Am Fam Physician contributor: fullname: Coles S – ident: e_1_3_2_7_2 doi: 10.1093/eurheartj/ehy339 – ident: e_1_3_2_18_2 doi: 10.1177/1740774514537404 – ident: e_1_3_2_19_2 doi: 10.1161/CIRCHEARTFAILURE.116.003613 – ident: e_1_3_2_31_2 doi: 10.1016/j.jacc.2018.01.074 – ident: e_1_3_2_23_2 doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 – volume: 2018 start-page: e13 issue: 71 year: 2017 ident: e_1_3_2_6_2 article-title: ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines publication-title: Hypertension contributor: fullname: Whelton PK – ident: e_1_3_2_11_2 doi: 10.1161/CIRCOUTCOMES.117.003624 – ident: e_1_3_2_10_2 doi: 10.1371/journal.pmed.1002410 |
SSID | ssj0000627359 |
Score | 2.400541 |
Snippet | There are no shared decision-making frameworks for selecting blood pressure (BP) targets for individuals with hypertension. This study addressed whether... Background There are no shared decision‐making frameworks for selecting blood pressure (BP) targets for individuals with hypertension. This study addressed... |
SourceID | doaj proquest crossref pubmed |
SourceType | Open Website Aggregation Database Index Database |
StartPage | e033995 |
SubjectTerms | Aged Antihypertensive Agents - therapeutic use Blood Pressure - drug effects Blood Pressure - physiology Decision Making, Shared Female Humans hypertension Hypertension - drug therapy Hypertension - physiopathology Male Middle Aged Patient Preference patient preferences Precision Medicine prediction Risk Assessment shared decision‐making Treatment Outcome |
Title | Incorporating Individual-Level Treatment Effects and Outcome Preferences Into Personalized Blood Pressure Target Recommendations |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39136305 https://www.proquest.com/docview/3092366745 https://doaj.org/article/be1b5e76a58f45fab32b44480a670c3b |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07T8MwELZQB8SCeFNeMhIDS6jzctKxRVRtRaFDK3WzbOe8kaImXZgQv4DfyC_hHKdVGRALa5TYzt3Z_s6--46QGwTFLDaB9EID6KBIDV7bZnIphdbjSz8w3CYnj554fxoNZ_Fso9SXjQlz9MBOcC0Fvooh4TJOTRQbiW2oCH0KJnnCdKiq1ZcFG86UW4NxW47bNZcPoprWsNO3B3_RHQttNuePbahi6_8dYlZbTW-P7NYYkXbc2PbJFuQHZHtU34Ifko-BJZ-sCIhx46GDdU7V1_vnow0CopNV-Dh17MQFlXlGn5cl2hfQ8bq2SIEfl3M6XiHyN8ho14ayU5c2uAA6qULFqXVTX7BFV4KpOCLT3sPkvu_VtRQ8HaRp6aUI3IzmkuOMNSHPWAIpcJXoAKXaBstpw2UCjEmdpei3RpLFGUpa43Me6zQ8Jo18nsMpodI3IYKMAAyDKDOg0OdBPywz2iB-0rxJbleiFa-OMkNUrgb3hdWCQC0Ip4Um6VrRr1-zXNfVA7QAUVuA-MsCmuR6pTiBc8NeeMgc5stChAzhK-dJhB2dOI2uu8JfCDkudmf_MYRzshMg2LFnzQG7II1ysYRLBCuluqrs8hv-oulJ |
link.rule.ids | 314,780,784,864,2102,27924,27925 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Incorporating+Individual-Level+Treatment+Effects+and+Outcome+Preferences+Into+Personalized+Blood+Pressure+Target+Recommendations&rft.jtitle=Journal+of+the+American+Heart+Association&rft.au=Ascher%2C+Simon+B&rft.au=Kravitz%2C+Richard+L&rft.au=Scherzer%2C+Rebecca&rft.au=Berry%2C+Jarett+D&rft.date=2024-08-20&rft.issn=2047-9980&rft.eissn=2047-9980&rft.volume=13&rft.issue=16&rft.spage=e033995&rft_id=info:doi/10.1161%2FJAHA.124.033995&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9980&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9980&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9980&client=summon |